Why neoadjuvant androgen deprivation prior to radical prostatectomy is unnecessary

Urol Clin North Am. 1996 Nov;23(4):587-604. doi: 10.1016/s0094-0143(05)70338-4.


Neoadjuvant hormonal therapy (NHT) prior to radical prostatectomy has been advocated for downstaging of tumors and reducing the rates of positive surgical margins with the expectation that disease-free survival will be improved. Despite the apparent favorable impact on pathologic findings, randomized trials to date show no benefit of NHT in prostate-specific antigen progression rates. Consequently, there is serious concern about the validity and biologic significance of the apparent downstaging and decreased rate of positive margins, and no evidence exists that there is improved time to progression and survival; therefore, the authors do not recommend NHT outside of a clinical trial.

Publication types

  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Androgen Antagonists / therapeutic use*
  • Chemotherapy, Adjuvant
  • Disease Progression
  • Hormones / therapeutic use*
  • Humans
  • Male
  • Neoplasm Staging
  • Prostatectomy*
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / pathology
  • Prostatic Neoplasms / surgery*
  • Randomized Controlled Trials as Topic


  • Androgen Antagonists
  • Hormones